1880
Parathyroid glands discovered
History
History of HypoPARAthyroidism
-
-
1908
W.G. MacCallum & Carl Voegtlin discovered connection between parathyroid glands and muscle spasms and calcium levels
-
1926
Dr. Hans Beumer and Dr. Curt Hermann Falkenheim describe the first case of non-surgical hypopara
-
1930's
Dr. Fuller Albright distinguished between the types of hypopara including pseudo
-
Aug 1994
The Hypoparathyroidism Association began as a quarterly newsletter
-
Jan 5, 1994
Halla Ruth was the 1st child dosed with teriparatide in Dr. Winer’s study and has remained on this treatment ever since.
-
Aug 1996
Dr. Winer’s trial of using teriparatide in children with hypopara at the NIH was published.
-
Apr 1998
The Association became incorporated as an official 501c3
-
Jan 2004
rhPTH 1-84 began clinical trials at Columbia University.
-
Apr 2004
InSeNSu was started in Germany.
-
Jul 2005
Hypopara UK was started by Liz Glenister with a little help from James Sanders.
-
Nov 2005
Nordic hypopara was started.
-
Apr 2006
The first HypoPARA conference was held.
-
Jan 2009
Hypopara Bahrain was started by Hassan Fadul.
-
Jun 2009
rhPTH 1-84 began phase III “REPLACE” trial.
-
Feb 2011
The "REPLACE" trial ended.
-
Jan 23, 2015
rhPTH 1-84 received FDA under the brand name Natpara.
-
Jul 2019
Transcon PTH began first in human trial on healthy adults.
-
Nov 2019
PATH Forward (Transcon PTH phase II) trial began dosing patients.
-
Sep 2020
Phase 2/2b trial of Encalaret for ADH1 begins.
-
Feb 2021
PaTHway Trial (Transcon PTH phase III) begins in Europe.
-
Apr 2021
PaTHway Trial begins in the U.S.
-
May 2021
Amolyt Pharma begins phase II study of eneboparatide.
-
Aug 2024
TransconPTH gets FDA approval under the brand name Yorvipath.
-
Sep 2024
Avail (phase II) study of canvuparatide begins.
-
Dec 2024
Yorvipath goes to market in the U.S.
-
Mar 2026
First pediatric trial for hypopara begins for Encalaret for ADH1.
-
May 2026
PaTHway60 trial begins for Yorvipath for doses over 30mcg.
Our Story
James Sanders, father of five sons with the rare disease of hypoPARAthyroidism, felt often alone and ill-equipped to cope with the challenges the disease brought to their daily lives in Idaho Falls, Idaho. In 1994, through a study at the National Institutes of Health (NIH), he first met another patient with this disease besides his children. It was then that the idea for an association dedicated to hypoparathyroidism patients was hatched. That year he began with a newsletter for both patients, family, and healthcare providers.
Now, with twenty plus years of hard work, we have grown a worldwide membership exceeding 5,000 members in 70 countries. We have since launched a website as a hub for patient support in partnership with doctors and researchers. We host an annual conference that includes speakers and attendees from across the globe. Our conferences further bring the medical and patient communities together for mutual exchange on how to treat and live with such a difficult disease.
In 1998, the HypoPARAthyroidism Association incorporated as a nonprofit and became a tax-exempt 501(c)(3) organization. As we’ve grown, we have excitedly supported numerous other associations’ creations in other countries around the globe. I am delighted to say, with our collective efforts, we have and will continue to make a difference in the lives of those touched by hypoPARAthyroidism. In the face of this disease, we need not feel alone. Through the Association and the work, we continue to push and grow, patients like me and my sons now have better access to information and research, skilled and knowledgeable doctors, and a robust, supportive, and understanding community. As I surmised back in 1994, clearly, together we can make a difference.
Jim Sanders
Founder, Board Member Emeritus
HypoPARAthyroidism Association, Inc.
Non-profit Tax EIN: 82-0505424